

Masato Yoshikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5829486/publications.pdf>

Version: 2024-02-01

7
papers

214
citations

1478505

6
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

348
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3343-3358.	6.4	7
2	TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies. <i>Cancer Research Communications</i> , 2022, 2, 489-502.	1.7	5
3	Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12228-12244.	6.4	25
4	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. <i>Chemical Research in Toxicology</i> , 2020, 33, 154-161.	3.3	9
5	Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. <i>Scientific Reports</i> , 2020, 10, 17081.	3.3	46
6	Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 <i>H</i> -pyrazolo[3,4- <i>c</i>]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure–Kinetic Relationships. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2384-2409.	6.4	78
7	CETSA quantitatively verifies <i>in vivo</i> target engagement of novel RIPK1 inhibitors in various biospecimens. <i>Scientific Reports</i> , 2017, 7, 13000.	3.3	44